Adrenaline for the Treatment of No-Reflow in Normotensive Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 201 participants.

Also called NCT04699110

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 201 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04699110
Other papers using this trial's data
  • Comparison of Intracoronary Epinephrine and Adenosine for No-Reflow in Normotensive Patients With Acute Coronary Syndrome (COAR Trial) Circulation. Cardiovascular interventions, 2022-02 DOI, PubMed 35000456, PMC8843359 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Pakistan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04699110. Randomized; no masking; primary purpose treatment. Start 2021-01-01 (actual); primary completion 2021-04-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Adrenaline for the Treatment of No-Reflow in Normotensive Patients
Condition
Acute Coronary Syndrome
Condition
No-Reflow Phenomenon
Condition
Normotensive
Intervention (Drug)
Adrenaline
Intervention (Drug)
Adenosine
Lead sponsor
National Institute of Cardiovascular Diseases, Pakistan (class: other)

Record details

Record id
cardio:ct-nct04699110
Content hash
29fd885329691325e4bce86c729622e2e974978dd8d7a83c4031cddfa45b2af9